Literature DB >> 30207246

A Review on The Role of VEGF in Tamoxifen Resistance.

Sepideh Mansouri1, Nikta Feizi1, Ali Mahdi1, Keivan Majidzadeh-A1,2, Leila Farahmand1.   

Abstract

BACKGROUND: Certain molecular deviations can lead to the development of breast cancer. For instance, estrogen and estrogen receptors play a significant role in inducing tumor proliferation. However, the efficacy of endocrine therapy through the administration of anti-estrogen drugs, such as Tamoxifen, is challenged by acquired resistance.
METHODS: Relevant articles were retrieved from Medline and google scholar. All were screened to select the ones discussing the molecular mechanisms of angiogenesis and Tamoxifen resistance. The molecular interactions contributing in the resistant network were studied from the eligible articles.
RESULTS: Tamoxifen resistance occurs as a consequence of over-activated signal transduction pathways such as RTK s dependent cascades. It has been shown that microvessel count was greater in Tamoxifen resistant tissues than in responsive ones.
CONCLUSION: In this review, the interaction between estrogen, Tamoxifen, VEGF, and VEGF receptors (VEGFRs) in Tamoxifen resistant cells has been discussed. VEGF and estrogen-independent growth cascades, especially MAPK have a positive feedback loop in Tamoxifen resistant cells. It has been proposed that over-activated pathways in Tamoxifen resistant cells induce pin1 mediated VEGF over-expression, which in turn result in enhanced activation of MAPK. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Angiogenesis; MAPK; VEGF; breast cancer; estrogen; molecular network; tamoxifen resistance.

Mesh:

Substances:

Year:  2018        PMID: 30207246     DOI: 10.2174/1871520618666180911142259

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  5 in total

Review 1.  Crosstalk between MUC1 and VEGF in angiogenesis and metastasis: a review highlighting roles of the MUC1 with an emphasis on metastatic and angiogenic signaling.

Authors:  Farnaz Khodabakhsh; Parnaz Merikhian; Mohammad Reza Eisavand; Leila Farahmand
Journal:  Cancer Cell Int       Date:  2021-04-09       Impact factor: 5.722

Review 2.  Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer.

Authors:  Chao Dong; Jiao Wu; Yin Chen; Jianyun Nie; Ceshi Chen
Journal:  Front Pharmacol       Date:  2021-03-15       Impact factor: 5.810

Review 3.  Progress in the Understanding of the Mechanism of Tamoxifen Resistance in Breast Cancer.

Authors:  Jingwei Yao; Kun Deng; Jialu Huang; Ruimin Zeng; Jianhong Zuo
Journal:  Front Pharmacol       Date:  2020-12-09       Impact factor: 5.810

4.  Knockdown of ATG4A inhibits breast cancer progression and promotes tamoxifen chemosensitivity by suppressing autophagy.

Authors:  Qingfang Li; Lingling Zan
Journal:  Mol Med Rep       Date:  2022-01-28       Impact factor: 2.952

5.  Design, synthesis and biological evaluation of a new thieno[2,3-d]pyrimidine-based urea derivative with potential antitumor activity against tamoxifen sensitive and resistant breast cancer cell lines.

Authors:  Marwa Sharaky; Marwa Kamel; Marwa A Aziz; Mervat Omran; Monira M Rageh; Khaled A M Abouzid; Samia A Shouman
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.